Mavyret (glecaprevir and pibrentasvir) is an oral treatment for all chronic hepatitis C virus (HCV) genotypes (1-6) in adult and pediatric patients 3 years and older.
Mavyret is FDA-approved for the treatment of adult and pediatric patients 3 years and older with:
- chronic HCV genotype (GT) 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A).
- HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor, but not both.
Hepatitis C is a viral disease that causes inflammation of the liver. Over time it can lead to diminished liver function or liver failure. There are at least six distinct HCV genotypes, or strains, which are genetically distinct groups of the virus.
In Americans who have HCV:
- Approximately 75 percent have genotype 1;
- 20-25 percent have genotypes 2 or 3;
- and a small number of patients are infected with genotypes 4, 5 or 6.
Mavyret is used to treat all six genotypes of HCV. Other medicines that are used to treat all six genotypes of HCV include:
- Vosevi (sofosbuvir, velpatasvir, and voxilaprevir) for the treatment of HCV in adults
- Epclusa (sofosbuvir and velpatasvir) for the treatment of HCV in adults and children 3 years of age and older.
Mavyret oral tablets and oral pellets are taken once daily with food for a treatment duration of between 8 and 16 weeks.